2Q EARNINGS: Celgene reports higher income on cancer drugs, raises estimates
This article was originally published in Scrip
Executive Summary
Celgene credited double-digit sales growth for a pair of drugs and a solid launch of a new blood cancer therapy as it reported better-than-expected profit. The company also raised its earnings forecast for the year.